GlassScriptPhysician profile
Richard Bleicher
NPI 1275584609
$53,472.06
in general payments reported to CMS, 2019-2025
7 companies · $635 in 2025
The $635 reported for 2025 was more than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.51 · 2020: $100 · 2022: $5,490 · 2023: $26K · 2024: $21K · 2025: $635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $21K · Honoraria: $19K · Travel and Lodging: $4,102 · Food and Beverage: $3,247 · Entertainment: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $21,300.00 |
| Honoraria | $19,000.00 |
| Travel and Lodging | $4,102.30 |
| Food and Beverage | $3,246.97 |
| Entertainment | $190.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Elucent Medical | $52,429.64 | 2022-2025 | |
| Kub Technologies INC. | $494.85 | 2023-2024 | Mozart |
| Endomagnetics LTD | $223.57 | 2019-2024 | Magseed, Magtrace |
| Daiichi Sankyo INC. | $105.48 | 2022-2024 | Enhertu |
| Eisai INC. | $104.22 | 2023 | |
| Merit Medical Systems INC | $100.37 | 2020 | |
| Tersera Therapeutics LLC | $13.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Bleicher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.